DOI:
10.1055/s-00034915
Onkologische Welt
LinksClose Window
References
Rugo HS. et al
Alpelisib + fulvestrant in patients with PIK3CA-mutated hormone-receptor positive (HR +), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer previously treated with cyclin-dependend kinase 4/6 inhibitor (CDKi) + aromatase inhibitor (AI): BYLieve study results..
ASCO 2020 Abstract 1006
Access:
We do not assume any responsibility for the contents of the web pages of other providers.